Waypoint Bio
AI-native biotech company designing next-generation CAR T therapies for solid tumors.
Technology stack
detected 2026-06-01Company Timeline
What does Waypoint Bio do?
Waypoint Bio is an AI-native biotechnology company focused on leveraging spatial biology and artificial intelligence to develop advanced CAR T therapies specifically for solid tumors. Their approach aims to overcome the limitations of current CAR T treatments, which have shown less efficacy in solid tumors compared to blood cancers. The company utilizes its proprietary AI platform to analyze complex biological data and design more effective and targeted therapeutic solutions.
How much funding has Waypoint Bio raised?
Waypoint Bio has raised a total of $135M in funding. The most recent round on record is Series A.
Where is Waypoint Bio headquartered?
Waypoint Bio is headquartered in New York, New York, USA.
When was Waypoint Bio founded?
Waypoint Bio was founded in 2021.
What industry does Waypoint Bio operate in?
Waypoint Bio operates in Biotechnology, Artificial Intelligence, Healthcare, Oncology, Biotech, Drug Discovery.
How many employees does Waypoint Bio have?
Waypoint Bio has approximately 20 people on record.